Abstract
High-dose cytarabine is currently used in combination with anthracycline in the treatment of acute myeloblastic leukaemia (AML). Moreover, high-dose cytarabine has been reported to produce long-term disease-free survival in a proportion of patients, especially in certain subtypes of AML. However, it remains unknown whether the outcome of patients undergoing allogeneic or autologous stem cell transplantation is influenced by previous treatment with high-dose cytarabine. To this end, 1672 patients with AML in first remission who were reported to the Acute Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT) and who were transplanted between 1980 and 1995 were analysed according to the dose intensity of cytarabine given at induction and/or consolidation. Autologous stem cell transplantation (ABMT) was performed in 846 patients and allogeneic bone marrow transplantation (BMT) in 826 patients. This study shows that the dose of cytarabine (Ara-C) given at induction and/or consolidation did not influence the relapse incidence in patients subsequently allografted or autografted. In addition, it did not give any advantage in terms of overall outcome. Therefore, high-dose (HD) Ara-C may not be needed for patients who have a planned stem cell transplantation (SCT) as post-remission therapy. Nevertheless, HD Ara-C may be utilized in certain subtypes of AML that are believed to be curable by chemotherapy alone.
| Original language | English |
|---|---|
| Pages (from-to) | 308-314 |
| Number of pages | 7 |
| Journal | British Journal of Haematology |
| Volume | 110 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Acute myeloblastic leukaemia
- Bone marrow transplantation
- Cytarabine
ASJC Scopus subject areas
- Hematology
Cite this
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. / Cahn, Jean Yves; Labopin, Myriam; Sierra, Jorge; Blaise, Didier; Reiffers, Josy; Ferrant, Augustin; Bergmann, Lothar; Visani, Giuseppe; Cornelissen, Jan; De Witte, Theo; Bosi, Alberto; Frassoni, Francesco; Gorin, Norbert Claude.
In: British Journal of Haematology, Vol. 110, No. 2, 2000, p. 308-314.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission
AU - Cahn, Jean Yves
AU - Labopin, Myriam
AU - Sierra, Jorge
AU - Blaise, Didier
AU - Reiffers, Josy
AU - Ferrant, Augustin
AU - Bergmann, Lothar
AU - Visani, Giuseppe
AU - Cornelissen, Jan
AU - De Witte, Theo
AU - Bosi, Alberto
AU - Frassoni, Francesco
AU - Gorin, Norbert Claude
PY - 2000
Y1 - 2000
N2 - High-dose cytarabine is currently used in combination with anthracycline in the treatment of acute myeloblastic leukaemia (AML). Moreover, high-dose cytarabine has been reported to produce long-term disease-free survival in a proportion of patients, especially in certain subtypes of AML. However, it remains unknown whether the outcome of patients undergoing allogeneic or autologous stem cell transplantation is influenced by previous treatment with high-dose cytarabine. To this end, 1672 patients with AML in first remission who were reported to the Acute Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT) and who were transplanted between 1980 and 1995 were analysed according to the dose intensity of cytarabine given at induction and/or consolidation. Autologous stem cell transplantation (ABMT) was performed in 846 patients and allogeneic bone marrow transplantation (BMT) in 826 patients. This study shows that the dose of cytarabine (Ara-C) given at induction and/or consolidation did not influence the relapse incidence in patients subsequently allografted or autografted. In addition, it did not give any advantage in terms of overall outcome. Therefore, high-dose (HD) Ara-C may not be needed for patients who have a planned stem cell transplantation (SCT) as post-remission therapy. Nevertheless, HD Ara-C may be utilized in certain subtypes of AML that are believed to be curable by chemotherapy alone.
AB - High-dose cytarabine is currently used in combination with anthracycline in the treatment of acute myeloblastic leukaemia (AML). Moreover, high-dose cytarabine has been reported to produce long-term disease-free survival in a proportion of patients, especially in certain subtypes of AML. However, it remains unknown whether the outcome of patients undergoing allogeneic or autologous stem cell transplantation is influenced by previous treatment with high-dose cytarabine. To this end, 1672 patients with AML in first remission who were reported to the Acute Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT) and who were transplanted between 1980 and 1995 were analysed according to the dose intensity of cytarabine given at induction and/or consolidation. Autologous stem cell transplantation (ABMT) was performed in 846 patients and allogeneic bone marrow transplantation (BMT) in 826 patients. This study shows that the dose of cytarabine (Ara-C) given at induction and/or consolidation did not influence the relapse incidence in patients subsequently allografted or autografted. In addition, it did not give any advantage in terms of overall outcome. Therefore, high-dose (HD) Ara-C may not be needed for patients who have a planned stem cell transplantation (SCT) as post-remission therapy. Nevertheless, HD Ara-C may be utilized in certain subtypes of AML that are believed to be curable by chemotherapy alone.
KW - Acute myeloblastic leukaemia
KW - Bone marrow transplantation
KW - Cytarabine
UR - http://www.scopus.com/inward/record.url?scp=0033840785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033840785&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.2000.02178.x
DO - 10.1046/j.1365-2141.2000.02178.x
M3 - Article
C2 - 10971386
AN - SCOPUS:0033840785
VL - 110
SP - 308
EP - 314
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -